Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Metadata listed "Alterity Therapeutics Ltd," but the filing text identifies the registrant as Prana Biotechnology Limited).
Reporting Period: November 2006 (Notice dated November 29, 2006).
Business Overview: Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related neuro-degenerative disorders. The company was incorporated in 1997, listed on the Australian Stock Exchange (ASX) in March 2000, and listed on NASDAQ in September 2002. Its technology was discovered by researchers at the University of Melbourne and Massachusetts General Hospital.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of securities issuance rather than a financial results report.
Material Changes and Securities Issuance
The primary material event reported is the issuance of securities without prior disclosure to investors under section 708A(5) of the Corporations Act 2001 (Cth). The Company has applied to the Australian Stock Exchange for quotation of these securities.
- Ordinary Shares: 15,616,246 fully paid ordinary shares issued on November 29, 2006.
- Options: 3,123,248 unlisted options issued on November 29, 2006.
- Option Terms: Exercisable at $0.446 on or before November 30, 2009.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary on future performance, or a discussion of risks and contingencies beyond the standard disclosure of the securities issuance.
Investor Verification Checklist
- Verify the current ticker symbols and listing status on NASDAQ and ASX, noting the discrepancy between the metadata company name and the filing registrant.
- Confirm the dilution impact of the issuance of 15,616,246 new ordinary shares and 3,123,248 options.
- Review the exercise price of $0.446 for the new options against the current market price to assess potential dilution.
- Check for subsequent filings regarding the approval of the securities quotation by the Australian Stock Exchange.